epirubicin has been researched along with Digestive System Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fridrik, M; Hausmaninger, H; Hehenwarter, W; Lehnert, M; Manfreda, D; Samonigg, H; Schiller, L; Sevelda, P; Steger, G; Tschurtschenthaler, G | 1 |
| Armand, JP; Evans, TR; Seymour, L | 1 |
2 trial(s) available for epirubicin and Digestive System Neoplasms
| Article | Year |
|---|---|
Randomised phase II study of epirubicin-vindesine versus mitoxantrone-vindesine in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Digestive System Neoplasms; Epirubicin; Female; Humans; Middle Aged; Mitoxantrone; Remission Induction; Soft Tissue Neoplasms; Survival Analysis; Vindesine | 1995 |
Raltitrexed (Tomudex) in combination with platinum-based agents and/or anthracyclines: preliminary results of phase I clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Digestive System Neoplasms; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Humans; Mesothelioma; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Thiophenes; Treatment Outcome | 1999 |